CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
ALXN1840drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04594252
NCT04594252Phase 1Completed
CompareCT.gov

A Phase 1, Open-label Study to Assess Copper Balance in Healthy Participants Following Administration of ALXN1840

Alexion Pharmaceuticals, Inc.·interventional·Posted Oct 20, 2020·Updated Aug 19, 2024

In Brief

A Phase 1 clinical trial evaluating ALXN1840 for Healthy. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The study will assess the change from baseline in mean daily copper balance in healthy participants with repeat-dose administrations of ALXN1840 over 2 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedOct 20, 2020
Enrollment StartJul 1, 2020
Primary CompletionNov 18, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.7 years ago

Interventions

ALXN1840drug

Administered orally as tablets.